Phoma betae, IgE, Serum
Use
This test is useful for establishing a diagnosis of an allergy to Phoma betae, defining the allergen responsible for eliciting signs and symptoms, identifying allergens responsible for allergic response or anaphylactic episodes, confirming sensitization prior to beginning immunotherapy, and investigating the specificity of allergic reactions to insect venom allergens, drugs, or chemical allergens. It is not useful in patients previously treated with immunotherapy to determine if residual clinical sensitivity exists or in cases where medical management does not depend upon identification of allergen specificity.
Special Instructions
Not provided.
Limitations
Some individuals with clinically insignificant sensitivity to allergens may have measurable levels of IgE antibodies in serum. Results must be interpreted in the clinical context. False-positive results may occur in patients with markedly elevated serum IgE (>2500 kU/L) due to nonspecific binding to allergen solid phases. Testing for IgE antibodies is not useful in patients before immunotherapy, in whom the management does not depend on identification of allergen specificity.
FDA ApprovedNew York Approved
Methodology
Immunoassay (FEIA)
Biomarkers
LOINC Codes
- 6216-6 - P betae IgE Qn
- 6216-6 - P betae IgE Qn
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL for every 5 allergens requested
Minimum Volume
0.3 mL for 1 allergen
Container
Preferred: Serum gel; Acceptable: Red top; Submission: Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
N/A
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 90 days |